Display options
Cite
Yu Y, Xu N, Cheng Q, et al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021;110126doi: 10.1016/j.celrep.2021.110126.
Yu, Y., Xu, N., Cheng, Q., Deng, F., Liu, M., Zhu, A., Min, Y. Q., Zhu, D., Huang, W., Feng, X., Jing, X., Chen, Y., Yue, D., Fan, Y., Shu, C., Guan, Q., Yang, Z., Zhao, J., Song, W., Guo, D., Liu, H., Zhao, J., Lan, P., Shi, Z., Liu, Y., Chen, X., & Liang, H. (2021). IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell reports, 110126. https://doi.org/10.1016/j.celrep.2021.110126
Yu, Yang, et al. "IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus." Cell reports vol. (2021): 110126. doi: https://doi.org/10.1016/j.celrep.2021.110126
Yu Y, Xu N, Cheng Q, Deng F, Liu M, Zhu A, Min YQ, Zhu D, Huang W, Feng X, Jing X, Chen Y, Yue D, Fan Y, Shu C, Guan Q, Yang Z, Zhao J, Song W, Guo D, Liu H, Zhao J, Lan P, Shi Z, Liu Y, Chen X, Liang H. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03. PMID: 34910942; PMCID: PMC8639452.
Copy Download .nbib Format: NLM
Share it on

Cell Rep. 2021 Dec 03;110126. doi: 10.1016/j.celrep.2021.110126. Epub 2021 Dec 03.

IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus.

Cell reports

Yang Yu, Na Xu, Qi Cheng, Fei Deng, Meiqin Liu, Airu Zhu, Yuan-Qin Min, Dan Zhu, Wenbo Huang, Xu Feng, Xizhong Jing, Ying Chen, Daoyuan Yue, Yawei Fan, Chang Shu, Qing Guan, Zifeng Yang, Jincun Zhao, Wenjun Song, Deyin Guo, Huanliang Liu, Jindong Zhao, Ping Lan, Zhengli Shi, Yingfang Liu, Xiaoping Chen, Huanhuan Liang

Affiliations

  1. School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
  2. School of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong 518107, China.
  3. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China.
  4. State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan, Hubei 430071, China.
  5. CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan 430071, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  6. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
  7. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, NHFPC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research. Beijing 100191, China.
  8. Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  9. State Key Laboratory of Respiratory Disease, Institute of Integration of Traditional and Western Medicine, Guangzhou Medical University, Guangzhou, Guangdong 510180, China.
  10. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China; Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China.
  11. State Key Laboratory of Protein and Plant Genetic Engineering, College of Life Sciences, Peking University, Beijing 100871, China.
  12. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China. Electronic address: [email protected].
  13. CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Science, Wuhan 430071, China. Electronic address: [email protected].
  14. School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China; Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong 510655, China. Electronic address: [email protected].
  15. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, Hubei 430030, China; Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei 430030, China. Electronic address: [email protected].
  16. School of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong 518107, China. Electronic address: [email protected].

PMID: 34910942 PMCID: PMC8639452 DOI: 10.1016/j.celrep.2021.110126

Abstract

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key factors participating in the cytokine storm. Here we demonstrate that interferon-induced protein 35 (IFP35) plays an important role in the cytokine storm induced by SARS-CoV-2 and influenza virus infection. We find that the levels of serum IFP35 in individuals with SARS-CoV-2 correlates with severity of the syndrome. Using mouse model and cell assays, we show that IFP35 is released by lung epithelial cells and macrophages after SARS-CoV-2 or influenza virus infection. In addition, we show that administration of neutralizing antibodies against IFP35 considerably reduces lung injury and, thus, the mortality rate of mice exposed to viral infection. Our findings suggest that IFP35 serves as a biomarker and as a therapeutic target in virus-induced syndromes.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: COVID-19; IFP35; biomarker and therapeutic target; cytokine storm; influenza virus

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

  1. Nature. 2020 Mar;579(7798):270-273 - PubMed
  2. Mediators Inflamm. 2020 Jul 16;2020:7527953 - PubMed
  3. Nature. 2013 May 23;497(7450):498-502 - PubMed
  4. Methods Mol Biol. 2010;588:33-41 - PubMed
  5. Lancet Respir Med. 2021 May;9(5):511-521 - PubMed
  6. N Engl J Med. 2020 Dec 10;383(24):2333-2344 - PubMed
  7. Nat Commun. 2017 Oct 16;8(1):950 - PubMed
  8. Nature. 2010 Mar 4;464(7285):104-7 - PubMed
  9. Virol J. 2011 Mar 04;8:97 - PubMed
  10. Molecules. 2017 Oct 18;22(10): - PubMed
  11. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13 - PubMed
  12. Methods Mol Biol. 2014;1180:31-43 - PubMed
  13. mBio. 2018 Mar 13;9(2): - PubMed
  14. Methods Mol Biol. 2012;901:117-35 - PubMed
  15. Nat Rev Immunol. 2020 Feb;20(2):95-112 - PubMed
  16. N Engl J Med. 2020 Apr 30;382(18):1708-1720 - PubMed
  17. BMC Infect Dis. 2021 Mar 5;21(1):241 - PubMed
  18. Immunity. 2020 Sep 15;53(3):685-696.e3 - PubMed
  19. JAMA. 2020 Jul 28;324(4):335-336 - PubMed
  20. Lancet. 2020 Mar 28;395(10229):1054-1062 - PubMed
  21. Crit Care. 2016 Mar 30;20:75 - PubMed
  22. J Med Virol. 2020 Jul;92(7):814-818 - PubMed
  23. Cell Res. 2021 Jul;31(7):818-820 - PubMed
  24. Curr Protoc Immunol. 2015 Aug 03;110:2.1.1-2.1.23 - PubMed
  25. Science. 2020 Jun 12;368(6496):1163 - PubMed
  26. Virulence. 2014 Jan 1;5(1):137-42 - PubMed
  27. EMBO Rep. 2006 Aug;7(8):774-8 - PubMed
  28. Front Immunol. 2018 Jun 15;9:1330 - PubMed
  29. Genes Immun. 2021 Jul;22(3):141-160 - PubMed
  30. Nat Commun. 2020 Jul 8;11(1):3410 - PubMed
  31. Trends Immunol. 2013 Mar;34(3):129-36 - PubMed
  32. Cell. 2020 Jul 9;182(1):50-58.e8 - PubMed
  33. Ageing Res Rev. 2015 Nov;24(Pt A):83-97 - PubMed
  34. Int J Mol Sci. 2018 Mar 23;19(4): - PubMed
  35. Virology. 2013 Jan 5;435(1):92-101 - PubMed
  36. EMBO Mol Med. 2020 Jul 7;12(7):e12421 - PubMed
  37. N Engl J Med. 2021 May 20;384(20):1899-1909 - PubMed
  38. J Virol. 2015 Sep;89(17):8806-15 - PubMed
  39. PLoS Pathog. 2018 Apr 26;14(4):e1007001 - PubMed
  40. Nat Immunol. 2020 Oct;21(10):1146-1151 - PubMed
  41. Immunopharmacol Immunotoxicol. 2018 Jun;40(3):250-255 - PubMed
  42. PLoS Pathog. 2018 Nov 13;14(11):e1007428 - PubMed
  43. Lancet Rheumatol. 2020 Aug;2(8):e465-e473 - PubMed
  44. Nat Rev Microbiol. 2018 Jan;16(1):60 - PubMed
  45. Eur J Clin Invest. 2021 Jan;51(1):e13429 - PubMed
  46. Front Immunol. 2020 Nov 30;11:570993 - PubMed
  47. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767 - PubMed
  48. Nat Med. 2020 Oct;26(10):1636-1643 - PubMed
  49. Science. 2020 Dec 18;370(6523):1464-1468 - PubMed
  50. N Engl J Med. 2021 Jan 7;384(1):20-30 - PubMed

Publication Types